Correlates of tumor development in patients with myotonic dystrophy
- 320 Downloads
Patients with myotonic dystrophy (DM) have recently been reported to be at increased risk of tumor development, but clinical associations related to this observation are unknown. We calculated the odds ratios (ORs) and 95 % confidence intervals (CI) of self-reported tumor development by patients’ demographic and clinical characteristics to evaluate factors associated with tumor development in DM patients, using data from the National Registry of Myotonic Dystrophy and Facioscapulohumeral Dystrophy Patients and Family Members. Of the 911 participants, 47.5 % were male and 85.7 % had DM type 1 (DM1). Compared to DM1, patients with DM type 2 (DM2) were older at registry enrollment (median age 55 vs. 44 years, p < 0.0001) and at DM diagnosis (median age 48 vs. 30 years, p < 0.0001); and more likely to be females (p = 0.001). At enrollment, 95 (10.4 %) DM patients reported a history of benign or malignant tumor. Tumors were associated with female gender (OR 1.9, 95 % CI 1.2–3.1, p = 0.007) and DM1 (OR 2.1, 95 % CI 1.1–4.1, p = 0.03). In a subgroup analysis of patients with blood-based DNA testing results (397 DM1, 54 DM2), repeat expansion size was not associated with tumor risk in DM1 (p = 0.26) or DM2 (p = 0.34). In conclusion, female gender and DM1 subtype, but not DNA repeat expansion size, were associated with increased risk of tumors in DM. Follow-up studies are warranted to determine if oncogenes associated with dystrophia myotonica-protein kinase are altered in DM, and to determine if repeat expansion size, as in our study, is not associated with tumor development.
KeywordsMyotonic dystrophy Comorbidity Neoplasms Risk factors Repeat expansion size
This study was supported in-part by the Intramural Research Program of the National Cancer Institute, USA, and the University of Rochester’s Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (NIH/U54/NS048843), the National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members (NIH/N01-AR-50-227450), and the National Center for Research Resources and the National Center for Advancing Translational Sciences (NIH: UL1 RR024160). Dr. Das is supported by the Preventive Medicine Residency Program, University of Maryland School of Medicine.
Conflicts of interest
- 1.Harper PS (2001) Myotonic dystrophy. WB Saunders, PhiladelphiaGoogle Scholar
- 3.Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 69:385PubMedGoogle Scholar
- 7.Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT, III, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20(10):2009–2020Google Scholar
- 10.Hilbert JE, Kissel JT, Luebbe EA, Martens WB, McDermott MP, Sanders DB, Tawil R, Thornton CA, Moxley RT III (2012) If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials 33:302–311PubMedCrossRefGoogle Scholar
- 25.Jansen G, Willems P, Coerwinkel M, Nillesen W, Smeets H, Vits L, Howeler C, Brunner H, Wieringa B (1994) Gonosomal mosaicism in myotonic dystrophy patients: involvement of mitotic events in (CTG)n repeat variation and selection against extreme expansion in sperm. Am J Hum Genet 54:575–585PubMedGoogle Scholar
- 26.Banuls J, Botella R, Palau F, Ramon R, Diaz C, Paya A, Carnero L, Vergara G (2004) Tissue and tumor mosaicism of the myotonin protein kinase gene trinucleotide repeat in a patient with multiple basal cell carcinomas associated with myotonic dystrophy. J Am Acad Dermatol 50:S1–S3PubMedCrossRefGoogle Scholar